RNA Therapeutics: The Evolving Landscape of RNA Therapeutics
Editat de Paloma H. Giangrande, Vittorio de Franciscis, John J. Rossien Limba Engleză Paperback – 13 apr 2022
Later sections discuss delivery technologies, remaining hurdles in research and translation, the therapy development process from the lab to the clinic, and novel RNA-based therapies currently in development.
- Features leading experts in the field of RNA therapeutics, spanning all classes of RNA therapies
- Provides a detailed examination of approved RNA therapies and lessons learned from failed therapeutics
- Covers all aspects of therapeutic discovery and preclinical development, as well as clinical translation, manufacturing and regulatory aspects
Preț: 904.27 lei
Preț vechi: 1326.62 lei
-32%
Puncte Express: 1356
Carte tipărită la comandă
Livrare economică 06-20 iulie
Livrare express 05-11 iunie pentru 162.04 lei
Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
Specificații
ISBN-13: 9780128215951
ISBN-10: 012821595X
Pagini: 472
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 191 x 235 x 32 mm
Greutate: 0.81 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 012821595X
Pagini: 472
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 191 x 235 x 32 mm
Greutate: 0.81 kg
Editura: ELSEVIER SCIENCE
Cuprins
SECTION 1 The world of RNA therapeutics: Available RNA tools to modulate cellular processes
1. Targeting chromatin: Transcriptional gene activation (saRNA)
2. Argonaute and TNRC6, partners in RNAi
3. Targeted RNA therapeutics for treatment of cancer and immunomodulation
4. Extrahepatic delivery of RNA to immune cells
SECTION 2 Learning from history
5. Aptamer-based protein inhibitors
6. Lessons learned from developing an oligonucleotide drug for a rare disease
SECTION 3 Delivery
7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics
SECTION 4 From bench to bedside
9. CMC and regulatory aspects of oligonucleotide therapeutics
10. CMC: Regulatory landscape
11. CMC and manufacturing
SECTION 5 From bench to bedside
12. RNA delivery for cancer gene therapy
13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions
1. Targeting chromatin: Transcriptional gene activation (saRNA)
2. Argonaute and TNRC6, partners in RNAi
3. Targeted RNA therapeutics for treatment of cancer and immunomodulation
4. Extrahepatic delivery of RNA to immune cells
SECTION 2 Learning from history
5. Aptamer-based protein inhibitors
6. Lessons learned from developing an oligonucleotide drug for a rare disease
SECTION 3 Delivery
7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics
SECTION 4 From bench to bedside
9. CMC and regulatory aspects of oligonucleotide therapeutics
10. CMC: Regulatory landscape
11. CMC and manufacturing
SECTION 5 From bench to bedside
12. RNA delivery for cancer gene therapy
13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions